1. Home
  2. IZM vs AKTX Comparison

IZM vs AKTX Comparison

Compare IZM & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICZOOM Group Inc.

IZM

ICZOOM Group Inc.

HOLD

Current Price

$1.37

Market Cap

16.8M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.26

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IZM
AKTX
Founded
2011
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.8M
14.4M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
IZM
AKTX
Price
$1.37
$0.26
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
95.8K
462.4K
Earning Date
10-24-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$187,048,691.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.60
N/A
Revenue Growth
5.12
N/A
52 Week Low
$0.87
$0.22
52 Week High
$2.74
$1.73

Technical Indicators

Market Signals
Indicator
IZM
AKTX
Relative Strength Index (RSI) 42.49 36.37
Support Level $1.30 $0.25
Resistance Level $1.49 $0.28
Average True Range (ATR) 0.21 0.02
MACD -0.07 0.01
Stochastic Oscillator 5.24 11.48

Price Performance

Historical Comparison
IZM
AKTX

About IZM ICZOOM Group Inc.

ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: